Allergan injects $370M into Esprit buyout

Allergan is taking some of the money it makes from Botox to buy Esprit Pharma for $370 million in cash. New Jersey-based Esprit makes Sanctura for overactive bladder and is launching Sanctura XR. Allergan says it plans to boost Esprit's sales force, which counts about 160 workers.

Allergan says the buyout makes a lot of sense, as it plans to expand its presence in the genitourinary market. Allergan is conducting early and mid-stage studies of Botox for idiopathic and neurogenic OAB. The company is betting that Sanctura and Sanctura XR can hit up to $400 million in annual sales.

- read the release on the buyout

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.